These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 19719973)
1. Efficacy and safety of induction therapy with alemtuzumab in kidney transplantation: a meta-analysis. Shou ZF; Zhou Q; Cai JR; Cheng J; He Q; Wu JY; Chen JH Chin Med J (Engl); 2009 Jul; 122(14):1692-8. PubMed ID: 19719973 [TBL] [Abstract][Full Text] [Related]
2. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients. Lü TM; Yang SL; Wu WZ; Tan JM Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554 [TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta-analysis. Hao WJ; Zong HT; Cui YS; Zhang Y Transplant Proc; 2012 Dec; 44(10):2955-60. PubMed ID: 23195005 [TBL] [Abstract][Full Text] [Related]
4. Pilot study of rapid steroid elimination with alemtuzumab induction therapy in kidney and pancreas transplantation. Sundberg AK; Roskopf JA; Hartmann EL; Farney AC; Rohr MS; Stratta RJ Transplant Proc; 2005 Mar; 37(2):1294-6. PubMed ID: 15848701 [TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation. Sampaio MS; Kadiyala A; Gill J; Bunnapradist S Transplantation; 2009 Oct; 88(7):904-10. PubMed ID: 19935462 [TBL] [Abstract][Full Text] [Related]
7. Alemtuzumab induction in deceased donor kidney transplantation. Shin M; Song SH; Kim JM; Kwon CH; Joh JW; Lee SK; Kim SJ Transplant Proc; 2011; 43(6):2365-78. PubMed ID: 21839271 [TBL] [Abstract][Full Text] [Related]
8. Alemtuzumab induction in kidney transplantation. Huang E; Cho YW; Shah T; Peng A; Hayashi R; Bunnapradist S Clin Transpl; 2005; ():343-54. PubMed ID: 17424750 [TBL] [Abstract][Full Text] [Related]
9. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781 [TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab induction in kidney transplantation: clinical results and impact on T-regulatory cells. Morales J; Bono MR; Fierro A; Iñiguez R; Zehnder C; Rosemblatt M; Calabran L; Herzog C; Benavente D; Aguiló J; Pefaur J; Alba A; Ferrario M; Simon W; Contreras L; Buckel E Transplant Proc; 2008 Nov; 40(9):3223-8. PubMed ID: 19010240 [TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab induction and triple maintenance immunotherapy in kidney transplantation from donors after cardiac death. Schadde E; D'Alessandro AM; Knechtle SJ; Odorico J; Becker Y; Pirsch J; Sollinger H; Fernandez LA Transpl Int; 2008 Jul; 21(7):625-36. PubMed ID: 18397178 [TBL] [Abstract][Full Text] [Related]
12. Induction with and without antithymocyte globulin combined with cyclosporine/tacrolimus-based immunosuppression in renal transplantation: a meta-analysis of randomized controlled trials. Tian JH; Wang X; Yang KH; Liu AP; Luo XF; Zhang J Transplant Proc; 2009 Nov; 41(9):3671-6. PubMed ID: 19917365 [TBL] [Abstract][Full Text] [Related]
13. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: rejection and infection rates in 40 recipients during the early postoperative period. Zanfi C; Lauro A; Cescon M; Dazzi A; Ercolani G; Grazi GL; Zanello M; Vivarelli M; Del Gaudio M; Ravaioli M; Cucchetti A; Vetrone G; Tuci F; Di Gioia P; Lazzarotto T; D'Errico A; Bagni A; Faenza S; Siniscalchi A; Pironi L; Pinna AD Transplant Proc; 2010; 42(1):35-8. PubMed ID: 20172276 [TBL] [Abstract][Full Text] [Related]
14. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Magliocca JF; Knechtle SJ Transpl Int; 2006 Sep; 19(9):705-14. PubMed ID: 16918530 [TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis. Morgan RD; O'Callaghan JM; Knight SR; Morris PJ Transplantation; 2012 Jun; 93(12):1179-88. PubMed ID: 22660659 [TBL] [Abstract][Full Text] [Related]
17. Experience with Alemtuzumab (Campath-1H) as induction agent in renal transplantation followed by steroid-free immunosuppression. Baez Y; Giron F; Niño-Murcia A; Rodríguez J; Salcedo S Transplant Proc; 2008 Apr; 40(3):697-9. PubMed ID: 18454990 [TBL] [Abstract][Full Text] [Related]
18. Campath-1H (alemtuzumab) as an induction agent for the prevention of graft rejection and preservation of renal function in kidney transplant patients: Philippine 3-year follow-up. Muñoz AS; Cabanayan-Casasola CB; Danguilan RA; Padua FB; Ona ET Transplant Proc; 2008 Sep; 40(7):2230-3. PubMed ID: 18790200 [TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - long-term results. Kaufman DB; Leventhal JR; Gallon LG; Parker MA Am J Transplant; 2006 Feb; 6(2):331-9. PubMed ID: 16426317 [TBL] [Abstract][Full Text] [Related]
20. Pediatric living donor kidney transplantation under alemtuzumab pretreatment and tacrolimus monotherapy: 4-year experience. Tan HP; Donaldson J; Ellis D; Moritz ML; Basu A; Morgan C; Vats AN; Erkan E; Shapiro R Transplantation; 2008 Dec; 86(12):1725-31. PubMed ID: 19104412 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]